TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - MODERNA | Market Closed - Deutsche Boerse AG 15:50:22 2024-06-28 EDT | ||
| 10.37 EUR | +2.67% |
|
| Current month | +28.50% | ||
| 1 month | +45.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 10.37 | +2.67% |
| 24-06-27 | 10.1 | +0.90% |
| 24-06-26 | 10.01 | +15.06% |
| 24-06-25 | 8.7 | +0.12% |
| 24-06-24 | 8.69 | -2.80% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 03:50 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| WKN | SH4SZ2 |
| ISIN | DE000SH4SZ23 |
| Date issued | 2022-01-11 |
| Strike | 229 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.38 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.38 € |
|---|---|
| Lowest since issue | 1 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Certificates
- Certificat
